| Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study H Gisslinger, C Klade, P Georgiev, D Krochmalczyk, ... The Lancet Haematology 7 (3), e196-e208, 2020 | 262 | 2020 |
| Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation P Gallego, V Roldán, JM Torregrosa, J Gálvez, M Valdés, V Vicente, ... Circulation: Arrhythmia and Electrophysiology 5 (2), 312-318, 2012 | 186 | 2012 |
| Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients V Roldán, F Marín, B Muiña, JM Torregrosa, D Hernández-Romero, ... Journal of the American College of Cardiology 57 (25), 2496-2504, 2011 | 168 | 2011 |
| High sensitivity cardiac troponin T and interleukin‐6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation V Roldan, F Marin, J Diaz, P Gallego, E Jover, M Romera, ... Journal of Thrombosis and Haemostasis 10 (8), 1500-1507, 2012 | 141 | 2012 |
| Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study S Verstovsek, AT Gerds, AM Vannucchi, HK Al-Ali, D Lavie, ... The Lancet 401 (10373), 269-280, 2023 | 76 | 2023 |
| Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients J Rohmer, A Couteau‐Chardon, J Trichereau, K Panel, C Gesquiere, ... American Journal of Hematology 95 (11), 1314-1323, 2020 | 47 | 2020 |
| A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML A Mekinian, LP Zhao, S Chevret, K Desseaux, L Pascal, T Comont, ... Leukemia 36 (11), 2739-2742, 2022 | 43 | 2022 |
| Post‐irradiation neuromyotonia affecting trigeminal nerve distribution: an unusual presentation JM Diaz, ES Urban, JS Schiffman, AC Peterson Neurology 42 (5), 1102-1102, 1992 | 39 | 1992 |
| Hermansky-Pudlak syndrome I Sánchez-Guiu, JM Torregrosa, F Velasco, AI Antón, ML Lozano, ... Hämostaseologie 34 (04), 301-309, 2014 | 34 | 2014 |
| Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies AG Kulasekararaj, M Griffin, S Langemeijer, K Usuki, A Kulagin, M Ogawa, ... European Journal of Haematology 109 (3), 205-214, 2022 | 32 | 2022 |
| Decitabine versus hydroxyurea for advanced proliferative CMML: results of the Emsco randomized phase 3 Dacota trial R Itzykson, V Santini, C Chaffaut, A Lionel, S Thepot, A Giagounidis, ... Blood 136, 53-54, 2020 | 27 | 2020 |
| Low‐dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment‐free remission in chronic myeloid leukemia patients: results of a retrospective study E Cayssials, J Torregrosa‐Diaz, P Gallego‐Hernanz, F Tartarin, ... Cancer 126 (15), 3438-3447, 2020 | 26 | 2020 |
| Conflict of interest JM Torregrosa, F Ferrer-Marın, ML Lozano Hematology 94, 789-794, 2015 | 25 | 2015 |
| Down regulation of the Munc18b-syntaxin-11 complex and β1-tubulin impairs secretion and spreading in neonatal platelets E Caparrós-Pérez, R Teruel-Montoya, V Palma-Barquero, JM Torregrosa, ... Thrombosis and Haemostasis 117 (11), 2079-2091, 2017 | 24 | 2017 |
| Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC K Augeul-Meunier, ML Chretien, AM Stoppa, L Karlin, L Benboubker, ... Bone Marrow Transplantation 53 (6), 749-755, 2018 | 23 | 2018 |
| CPX 351 as first line treatment in higher risk MDS. A Phase II trial by the GFM P Peterlin, P Turlure, P Chevallier, MP Gourin, PY Dumas, S Thepot, ... Blood 138, 243, 2021 | 21 | 2021 |
| The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms G Soler, A Bernal-Vicente, AI Antón, JM Torregrosa, E Caparrós-Pérez, ... Annals of hematology 94, 789-794, 2015 | 15 | 2015 |
| Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next … F Ferrer-Marín, B Bellosillo, L Martínez-Avilés, G Soler, P Carbonell, ... Journal of hematology & oncology 6, 1-5, 2013 | 15 | 2013 |
| Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real‐life study T Comont, M Meunier, A Cherait, C Santana, T Cluzeau, B Slama, K Laribi, ... British Journal of Haematology 194 (2), 336-343, 2021 | 13 | 2021 |
| Developmental differences in platelet inhibition response to prostaglandin E1 V Palma-Barqueros, JM Torregrosa, E Caparrós-Pérez, N Mota-Pérez, ... Neonatology 117 (1), 15-23, 2020 | 13 | 2020 |
